Human medicines
The Estonian human medicinal products market was 143 million euros in wholesale prices in the first quarter of 2026. Compared to the same period of the previous year, the turnover increased 8.4%. The market of human medicines by quarter during last five years is on Figure 1.
Figure 1. Human medicinal products market by quarters, in 2022–2026.
During Q1 2026 there were 25 licensed medicinal product wholesalers, who distributed human medicines to general or hospital pharmacies or to other institutions in Estonia.
Sales to general pharmacies covered 70.6%, sales to hospital pharmacies 28.8% and sales to other institutions 0.6% of total medicinal products market. The sales of prescription medicines covered 88% and the sales of over-the-counter medicines 12% of the pharmaceutical market.
The most used medicines by DDD/1000/day were cardiovascular system medicines (480 DDD/1000/day), followed by alimentary tract and metabolism medicines (203 DDD/1000/day) and nervous system medicines (180 DDD/1000/day). These three ATC groups covered 63% of overall medicines consumption in Estonia in Q1 2026. Altogether 1376 different active substances were marketed, and the most used active substances were Rosuvastatin (74 DDD/1000/day), Ramipril (47 DDD/1000/day), and Atorvastatin (45 DDD/1000/day).
The most sold medicines by turnover were antineoplastic and immunomodulating agents (41 million euros), alimentary tract and metabolism medicines (21 million euros) and medicines for nervous system (14 million euros). The market share of these three ATC groups was altogether 53%
Human medicines I quarter 2026 in summary:
Medicinal products market: 143 million euros
Sales to pharmacies: 101 million euros
Sales to hospital pharmacies: 41 million euros
Sales to other institutions: 1 million euros
Antineoplastic and immunomodulating agents: 41 million euros
Alimentary tract and metabolism: 21 million euros
Medicines for nervous system:14 million euros
Veterinary medicines
The Estonian veterinary medicinal products market was 5.0 million euros in wholesale prices in the first quarter of 2026. Compared to the same period of the previous year the turnover decreased 2%. From the overall sales, 90% of veterinary medicines were sold to the veterinarians or to the agricultural companies represented by a veterinarian, and 10% to the general and veterinary pharmacies.
Figure 2. Veterinary medicinal products market (medicines used in animals) by quarters, in 2022–2026
The most sold medicines by turnover were antiparasitic products, followed by immunologicals and antiinfectives for systemic use, accounting for 29%, 20% and 15% of total veterinary medicines sales, respectively.
Veterinary medicines I quarter 2026 in summary:
Veterinary medicinal products market: 5.0 mil euros
Sales to veterinarians: 4.5 mil euros
Sales to general and veterinary pharmacies: 0.5 mil euros
Antiparasitic products (QP): 1.4 mil euros
Immunologicals (QI): 1.0 mil euros
Antiinfectives for systemic use (QJ): 0.7 mil euros
